Who
Damon DeSantis
Director
Company insider
Files Form 4 as: Director, Celsius Holdings; Director and 10% owner, Integrated Biopharma.
In numbers
- Trades disclosed
- 22
- Buys
- 2
- Sells
- 0
- Bought
- $2.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 28 Oct 2021
- Last trade
- 15 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Sep – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 15 Sep 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Bought | $447K16,000 at $27.95 | filing |
| 15 Sep 2026filed 15 Sep 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Bought | $447K16,000 at $27.95 | filing |
| 14 Sep 2026filed 15 Sep 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Bought | $553K20,000 at $27.65 | filing |
| 14 Sep 2026filed 15 Sep 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Bought | $553K20,000 at $27.65 | filing |
| 24 Jun 2026filed 25 Jun 2026 | Integrated Biopharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | Integrated Biopharma | SEC FORM 4 Code G | —8,966,547 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | Integrated Biopharma | SEC FORM 4 Code G | —2,235,417 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | Integrated Biopharma | SEC FORM 4 Code G | —1,356,293 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | Integrated Biopharma | SEC FORM 4 Code G | —7,392 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code A | —2,611 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code A | —2,611 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | Integrated Biopharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code A | —4,865 at $0.00 | filing |
| 7 Aug 2024filed 8 Aug 2024 | Integrated Biopharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code G | —1,965,988 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code A | —1,576 at $0.00 | filing |
| 18 Jul 2023filed 19 Jul 2023 | Integrated Biopharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jan 2023filed 27 Mar 2023 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code G | —232,994 | filing |
| 1 Jan 2023filed 5 Jan 2023 | CELH Celsius HoldingsBeverages | SEC FORM 4 Code A | —1,105 | filing |
| 20 Jun 2022filed 21 Jun 2022 | Integrated Biopharmaoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
Celsius Director Damon DeSantis Buys 36,000 Shares for $1.0 Million. Is This a Buy Signal?fool.com · 16 Sep 2026Celsius (NASDAQ:CELH) Director Damon Desantis Buys 20,000 Sharesthemarketsdaily.com · 16 Sep 2026Jim Cramer Likes Part of the Celsius (CELH) Story but Something Is MissingCELH · insidermonkey.com · 11 Oct 2026ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Celsius Holdings, Inc. Investors to Secure Counsel ...CELH · gazettextra.com · 11 Oct 2026Pomerantz LLP Files Class Action Lawsuit Against Celsius Holdings, ...CELH · pr-inside.com · 10 Oct 2026
2 headlines in the last 90 days name Damon DeSantis; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.